Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final test

Bristol Myers Squibb will push its TYK2 inhibitor into phase 3 trials for lupus later this year off the back of positive midstage data as the drug awaits a key FDA decision for psoriasis.